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Tuberculosis (TB) disease still kills 1-person every 21-seconds. Few TB diagnostic tests are considered 
truly appropriate for point of care settings. The WHO-endorsed immunodiagnostic Alere Determine 
Lipoarabinomannan Ag-test (LAM-test) detects Mycobacterium tuberculosis complex LAM in urine, and 
its use is recommended for TB diagnosis among HIV co-infected individuals with low CD4 T-cell counts. 
Here we found that a simple 15-minute enzymatic treatment at room temperature of LAM-spiked urine 
with α-mannosidase (for human TB), and LAM-spiked milk with combined lactase and caseinase (for 
bovine TB), enhanced 10-fold the detection levels of the LAM-test and thus, improved the detection 
of LAM by the LAM-test in urine and milk that otherwise could be missed in the field. Future separate 
clinical research studies specifically designed to address the potential of these findings are required.
Tuberculosis (TB) is the leading cause of death by a single infectious disease1. The Mycobacterium tuberculosis 
(M.tb) complex cell wall has many cell wall components that are being evaluated for diagnosis purposes. One 
of them is the lipoglycan so called mannose-capped lipoarabinomannan (LAM)2–4, which is found in urine of 
active TB patients2–8. To date, the only WHO supported TB point-of-care (POC) test is the Alere Determine 
Lipoarabinomannan (LAM) Ag test (LAM-test)9. This test is based on polyclonal antibodies of unknown specific-
ity recognizing LAM in urine, as an indicator of TB disease7,10. The LAM-test best performance is in HIV-positive 
individuals with CD4 T cells counts below 50/mm3 of blood (52% sensitivity/98% specificity)7,10,11.
To improve the sensitivity of this test, we closely looked at the structure of the M.tb complex mannose-capped 
LAM or ManLAM (reviewed in4), ManLAM (from here on called LAM) is composed of a GPI-anchor, arabi-
nan and mannan domains, and mannose caps4. The number of caps, length and branching of the arabinan and 
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mannan domains, number of succinates, and the number and nature of fatty acids in the GPI-anchor makes this 
an extremely heterogeneous molecule4. A unique methylated thio-xylofuranose (MTX) is attached to a single 
mannose-cap of LAM4, being described in susceptible and drug resistant M.tb strains (Fig. 1A)4. MTX detection 
is the basis for the new (Foundation for Innovative New Diagnostics (FIND) supported POC Fujifilm/SILVAMP 
TB-LAM (FujiLAM) test, being tested in field diagnostic validation trials12–14.
Based on the high LAM structural complexity4, and the low sensitivity of the LAM-test7,10,11, we rationalized 
that the complex LAM molecule could be associated with other molecules (phospholipids, immunoglobulins, 
creatinine, etc.) in urine and/or milk that could made it less likely to be recognized by antibodies15,16. Thus, we 
biochemically treated LAM-spiked urine or milk to improve the LAM-test performance for the diagnosis of 
human and bovine TB. Out of several treatments tested (organic solvent delipidation, Proteinase-K, non-specific 
esterase, phospholipase, phosphatase, urease, creatinase, α-mannosidase, caseinase, and/or lactase treatments), 
our results showed that α-mannosidase treatment of LAM-spiked urine (for human TB) and combined lactase/
caseinase treatment of LAM-spiked milk (for bovine TB) enhanced 10-fold the detection levels of the LAM-test 
in laboratory settings.
Results
Improving LAM-test detection in LAM-spiked urine in the laboratory setting. First, using urine 
spiked with purified M.tb H37Rv LAM, we determined that the minimal amount of LAM that the LAM-test 
detects in urine is 0.0005 μg (or 500 pg, Fig. 1B). We further observed that at higher LAM concentrations (50–200 
μg of LAM/ml of urine), the detection of soluble LAM by the LAM-test was worse. We also observed that the 
optimal recognition of LAM by the LAM-test ranged from 0.05–10 μg of LAM/ml of urine (Fig. 1B). Importantly, 
in repeated experiments, we found consistent results.
Seeking methods to improve the LAM-test in a POC setting, we evaluated several field feasible options; the 
first, urine delipidation removing inherent lipids that could interfere with the LAM-test detection, and second, 
urine enzymatic treatment with different hydrolytic enzymes. Our results indicate that extracting with chloro-
form lipids present in urine spiked with 0.001 μg (or 1 ng) of LAM, we were able to increase the band intensity 
detection of the LAM-test (Fig. 1C), inferring that LAM molecules were detected better. This result indicates that 
natural lipids present in urine interfere with the LAM-test performance.
Figure 1. (A) Structure of mannose-capped lipoarabinomannan (ManLAM) present in all M.tb complex 
strains. ManLAM (depicted here as LAM) is a heterogeneous molecule comprised of a GPI-anchor, which 
can contain from 1–4 fatty acids, an α-(1 → 6) mannan core with multiple branches of a single mannose, an 
α-(1 → 5) arabinan core with multiple branches of different length at the C3 position of some arabinoses. 
The non-reducing end of some of these arabinan branches are decorated with 2-α-mono-, di- and tri-
mannosaccharide caps. A 5-methyl-thio-xylose (MTX) is present per LAM molecule, being the epitope 
recognized by the new FujiLAM test. LAM also contains succinate motifs, which biological function is still 
unclear but participate in determining the spatial conformation of LAM. (B) Alere Determine LAM Ag test 
(LAM-test) performed in M.tb H37Rv LAM spiked urine determining that the lowest amount that this test can 
detect LAM in urine is 0.0005 μg/ml of urine (500 pg). (C) A quick delipidation step for LAM spiked urine 
using chloroform (CHCl3) improves the detection of LAM by the LAM-test. Student’s t test, treatment vs. non-
treatment, n = 3–8, using LAM spiked urine from different human donors; ***p < 0.0005.
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Importantly, out of all the enzymatic treatments tested, when urine spiked with 0.001 μg of LAM from dif-
ferent M.tb strains was treated with 0.1 IU of α-mannosidase at room temperature, results showed that this very 
simple step done before performing the LAM-test significantly increased the intensity of the LAM-test detection 
band (Fig. 2A). This α-mannosidase treatment removes terminal 2-linked mannose residues in both, the man-
nose caps and from the single 2-mannose branched mannan-core of LAM (Fig. 1A). We observed this improve-
ment in LAM-test detection in urine spiked with structurally diverse LAMs obtained from different M.tb strains. 
(Fig. 2A). Further, using M.tb H37Rv LAM spiked urine, α-mannosidase treatment increased LAM-test detection 
levels to be as low as 0.00005 μg (or 50 pg) of LAM/ml of urine, a 10-fold detection improvement when compared 
to the LAM-test without α-mannosidase treatment of urine, which could only detect as low as 0.0005 μg/ml of 
urine (Figs. 1B and 2B). Interestingly, although the LAM-test was not consistent in detecting LAM from different 
strains of M.tb, at lower levels (0.0005 μg), it was capable of detecting structurally different LAMs from different 
M.tb strains (Fig. 2B). As expected, controls consisting of α-mannosidase treatment of non-spiked LAM urine 
were LAM-test negative (data not shown).
Improving LAM-test detection in LAM-spiked milk. We further assessed the efficiency of the LAM-test 
to detect LAM in milk, an easy specimen to obtain in the field, for the purpose of determining if the LAM-test 
could be used for the bovine TB diagnosis in a POC setting. Unexpectedly, no improvement was observed with 
LAM-spiked milk treated with α-mannosidase (data not shown). Indeed, the LAM-test was able to detect LAM 
in milk and detection levels were 10-fold improved (from 0.001 μg/ml to 0.0001 μg/ml) after LAM-spiked milk 
was treated with both caseinase and lactase (Fig. 2C).
Discussion
Currently, there are three tests for the detection of LAM (whole or fragmented) in human samples, the LAM-test7, 
the Lionex test17, and the new FujiLAM test18. Of these, currently only the LAM-test is WHO supported for 
the diagnosis and screening of active TB in people living with HIV9,19. In order to improve the efficacy of this 
test in detecting LAM in urine, we accounted for the LAM structural characteristics and how urine acts as a 
buffer. Without further sample manipulation, the LAM-test could detect as low as 0.0005 μg of LAM/ml of urine. 
Interestingly, we encountered that large amounts of LAM in urine interfered with the reading in a way that the 
intensity of the visible band on the LAM-test strip had lower intensity at the LAM concentrations ranging from 
100–200 μg/ml. This could be due to micelle formation of LAM in urine affecting the LAM epitopes disposition 
of being recognized by the LAM-test polyclonal antibodies. In this regard, LAM contains up to 4 fatty acids and 
thus, LAM micelle formations in aqueous buffers have been described20. Nonetheless, LAM-test higher band 
intensities were observed in concentrations between 50 and 0.01 μg/ml of urine. In this regard, other studies 
Figure 2. (A) Alere Determine LAM Ag test (LAM-test) performed in M.tb H37Rv, H37Ra, Erdman (Erd) or 
HN878 LAM-spiked urine treated with α-mannosidase to remove the mannose-caps of LAM. (B) A quick 
α-mannosidase treatment step for LAM-spiked urine (from two different M.tb strains, H37Rv (upper graph) and 
HN878 (lower graph) allows the detection of this molecule in urine by the LAM-test at lower concentrations. 
(C) Lactase and caseinase treatment of LAM-spiked milk also allows the detection of this molecule in milk by 
the LAM-test at lower concentrations. Student’s t test, treatment vs. non-treatment, n = 3–6, using LAM-spiked 
urine/milk from different human/animal donors; *p < 0.05; **p < 0.005; ***p < 0.0005.
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have demonstrated a semi-quantitative relationship between LAM concentration and band intensity of the LAM 
test7,21–23, and others suggested that a darker LAM band intensity relates to a greater bacillary load of M.tb24–26. No 
detection of LAM was observed in concentrations below 0.0005 μg/ml of urine.
A quick step involving the removal of lipids allowed us to detect LAM in urine better. These results were 
observed in urine spiked with virulent M.tb H37Rv and the attenuated M.tb H37Ra LAM types; however, this was 
not observed for the M.tb Erdman LAM. This indicates the importance of the LAM structure from different M.tb 
strains (reviewed in4,27) and their spatial conformation when dissolved in urine, as well as the interactions of LAM 
molecules with other lipids present in urine in determining how well the LAM-test detects this molecule.
After exposure of urine to several enzymatic treatments (Proteinase-K, non-specific esterase, phospholipase, 
phosphatase, urease, creatinase) failed to improve the LAM-test (data not shown), we opted to determine if the 
removal of the mannose-caps from LAM using α-mannosidase was able to further enhance the detection of 
this molecule by the LAM-test in urine. Our results indicate that a 15-minutes treatment of urine with 0.1 IU of 
α-mannosidase in the lab setting enhanced the recognition of LAM by the LAM-test. This result was observed 
for the LAMs of all M.tb strains tested. Thus, removal of the mannose caps of LAM may uncover specific arabi-
nan epitopes of this molecule and probably also changes its spatial conformation, increasing the affinity of the 
LAM-test polyclonal antibodies to recognize and bind LAM, increasing by 10-fold the detection levels of this test.
Finally, we determined if the LAM-test could be useful to detect LAM in milk, and thus be used as a POC 
test in farms for the detection of Bovine TB in cattle. Bovine TB is an increased global health problem, with 
areas around the globe where 15–25% of human TB cases are directly related to Mycobacterium bovis infection 
through zoonotic transmission or consumption of M. bovis contaminated products (i.e. unpasteurized milk)28. 
The LAM-test could in fact detect well LAM in milk at the lowest concentration of 0.001 μg/ml of milk. This is in 
contrast to the LAM concentration of 0.0005 μg that this test could detect in urine, indicating that milk contains 
soluble components that interfere with the detection of LAM by the LAM-test. In order to improve LAM detec-
tion in milk, we tried different methods (delipidation, Proteinase-K treatment, α-mannosidase, centrifugation 
to analyze the plasma milk phase, etc., data not shown); however, in our hands, only the combination of lactase 
and caseinase treatment resulted in an improvement of LAM detection in milk, where the LAM-test was able to 
detect as low as 0.0001 μg/ml (or 100 pg/ml), a 10-fold improvement relative to non-enzymatically treated milk. 
As a caution, in milk samples and in some instances, we observed that when the LAM-test was repeated, exact 
band intensity readings were not repeated. However, in our LAM-test studies an initial positive reading [1+ to 
4+] never gave us a negative reading [0] or vice versa when the LAM-test was repeated. This variation in band 
intensity from repeated tests using LAM-spiked milk samples is a concern that somehow gets mitigated with 
the current reading card of the LAM-test, where the appearance of a positive band at any intensity (+1 to +4) is 
indicative of a positive detection.
Overall these studies attempted to improve the LAM detection levels in urine/milk by the commer-
cially available LAM-test. Two quick steps, one in urine (α-mannosidase treatment) and one in milk (lactase/
caseinase-combined treatment), both for 15-minutes at room temperature, significantly reduced the concen-
trations of LAM in these specimens that could be detected by the LAM-test. All these enzymatic treatments can 
be easily performed in the field as part of the POC LAM-test, adding only 15 minutes to the 25 min that this test 
already requires. Importantly, from the point of view of the added cost, currently the LAM-test cost is US$3.5 
per test. The addition of the α-mannosidase urine treatment will add the cost of US$0.45 to the LAM-test; and 
the combined addition of lactase and caseinase milk treatment will add the cost of US$0.48 per test, allowing the 
detection of lower concentrations of LAM by the LAM test that otherwise will be missed.
A major limitation of this study is that the α-mannosidase treatment was tested on urine and milk spiked with 
purified bacterial LAM, and thus the need for separate clinical research studies specifically designed to address 
the potential of our findings. Our current efforts are directed to test this treatment in ongoing pilot studies in dif-
ferent high TB burden sites (e.g. Guatemala, Ethiopia, Mozambique). It is thought that immunological properties 
of LAM detected in the urine of TB patients are quite different from those of the antigen directly purified from 
bacteria18, thus future field studies will determine if α-mannosidase treatment of urine allows better detection of 
the natural secreted form of LAM in urine from active TB patients.
These fast and easy to perform biochemical treatment could potentially also improve other POC tests, such as 
the novel FujiLAM, which detects the MTX present in the mannose-caps of LAM (FIND personal communica-
tion). In this instance, treatment with α-mannosidase should remove all mannose-caps from ManLAM except the 
one containing MTX, and thus, potentially this could be better exposed to the recognition by FujiLAM test spe-
cific MTX Abs. This hypothetical reasoning will need to be further evaluated in future studies when the FujiLAM 
test will be commercially available.
Further studies are required to replicate and corroborate our laboratory results in field settings with scarce 
diagnostic techniques and delayed diagnosis29 using urine from human subjects with presumable symptoms of 
active TB, as well as using milk from cattle presumable with symptoms of bovine TB.
Methods
Human subjects and ethics statement and specimens. All experiments involving human specimens 
(urine) were performed in accordance with relevant guidelines and regulations. For laboratory studies, pre-ex-
isting human urine samples were obtained from anonymous healthy volunteers [Human Subjects Institutional 
Review Board (IRB) exempted research approved by UT-Health San Antonio IRB] in Texas.
Whole milk was obtained from unidentified healthy cows from an Ohioan farm (IACUC exempt, no animal 
manipulations). All specimens were spiked with known amounts of in-house purified LAMs30,31, as indicated in 
figures and figure legends, from different laboratory reference M.tb strains (H37Rv, H37Ra, Erdman) and from a 
hypervirulent M.tb clinical isolate (HN878)30.
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Alere determine urine LAM Ag test (LAM-test). LAM-tests were performed as indicated by the manu-
facturer instructions. Urine (60 μL) was applied to LAM-test strips followed by incubation at room temperature 
for 25 minutes. LAM-test results were then inspected by the naked-eye. In the lab setting, the intensity of any 
visible band on the LAM-test was graded as positive and from +1 (minimum intensity) to +4 (maximum inten-
sity) depending on its intensity and following the post 2014 reference card (new grades from +1 to +4) provided 
by the manufacturer. Readings were independently performed by two to three researchers in a blinded manner 
following manufacturer’s instructions.
Delipidation of urine and milk. Chloroform was added to LAM-spiked urine/milk 1:1 (v/v), hand mixed 
and led settle for 15 minutes at room temperature until bipartition was observed. The aqueous phase containing 
LAM was then directly used to perform LAM-tests following manufacturer’s instructions.
Enzymatic treatments of urine and milk. Proteinase-K, non-specific esterase, phospholipase, phos-
phatase, urease, or α-mannosidase, (each at 0.1 IU, Sigma-Aldrich, Saint Louis, MO) was added to 150 μl of 
LAM-spiked urine, and lactase and caseinase (both at 0.1 IU, Sigma-Aldrich) were added to 150 μl of LAM-spiked 
milk at the concentrations indicated in the figures and figure legends, hand mixed and further incubated for 
15 minutes at room temperature. Enzymatically treated LAM-spiked urine or milk was then directly used to per-
form LAM-tests following manufacturer’s instructions.
Statistical analysis. Experiments were performed using urine or milk from different human or animal 
donors, respectively. Unpaired two-tailed Student’s t-test was used for two group comparisons (delipidation/
enzymatic treatment vs. non-treatment). Statistical significance was determined using Prism 4 GraphPad software 
and reported as *p < 0.05; **p < 0.005; ***p < 0.0005.
Data availability
All materials, data and associated protocols will be promptly available to readers upon proper request.
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